Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +1.00p +1.33% 76.00p 343,866 08:26:07
Bid Price Offer Price High Price Low Price Open Price
76.00p 76.20p 76.20p 74.00p 74.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 103.32 28.37 6.10 12.5 391.5

Alliance Pharma (APH) Latest News

More Alliance Pharma News
Alliance Pharma Takeover Rumours

Alliance Pharma (APH) Share Charts

1 Year Alliance Pharma Chart

1 Year Alliance Pharma Chart

1 Month Alliance Pharma Chart

1 Month Alliance Pharma Chart

Intraday Alliance Pharma Chart

Intraday Alliance Pharma Chart

Alliance Pharma (APH) Discussions and Chat

Alliance Pharma Forums and Chat

Date Time Title Posts
21/9/201807:57Alliance Pharma pays Dividends1,031
21/8/201817:36A Canadian Stock Worth Watching1
07/11/201615:35Alliance Pharma plc1
15/7/201310:15ALLIANCE PHARMA – 2005 Strong Riser611

Add a New Thread

Alliance Pharma (APH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Alliance Pharma trades in real-time

Alliance Pharma (APH) Top Chat Posts

Alliance Pharma Daily Update: Alliance Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker APH. The last closing price for Alliance Pharma was 75p.
Alliance Pharma has a 4 week average price of 71.40p and a 12 week average price of 71.40p.
The 1 year high share price is 102.50p while the 1 year low share price is currently 53p.
There are currently 515,127,294 shares in issue and the average daily traded volume is 2,384,547 shares. The market capitalisation of Alliance Pharma is £386,345,470.50.
dround87: Massive buy and share price goes down. Can anyone explain that to a noob?
joeywald: It looks more like a reduction (from 9.90% to 4.78%). Either way, a positive effect on the share price!
123prezzie: I have held APH for a long time, first (after a company visit)with the Loan Notes and then, on conversion, the Ordinaries. I regard it as steady share which doesn't need much attention. I think that the share price hasn't sparkled because of several factors, • There isn't a story which can excite commentators or investors. They seem to buy things here and there when cash flow allows. Admittedly they did use shares for the Sinclair deal but all this did was reduce the price. • By comparison, I also hold shares in two similar companies, Clinigen and Venture Life. CLIN is acquisitive but has a clear story to tell and a price to match. VLG is a newcomer on a similar path and does trade with APH in a small way. • APH's record so far has not excited and the problem with keeping on spending hard earned cash on acquisitions is that the intangibles dominate the balance sheet. Shareholders' Equity is shown as £187m (market cap £250m) but this includes £263m of intangibles. As far as I can establish, if a product line doesn't perform, they don't write off the associated Goodwill, they just assume that if profits are going up there is no need for an impairment charge. What happens if a major product goes off the boil? • I have argued that the company, being low growth, should be more investor friendly and pay a higher dividend that they could well afford. This would help the share price but John Dawson doesn't want to play it that way. • What is ignored by investors (because it is obscured by the constant outflow on acquisitions) is the fantastic cash flow. Mind you, even if they stopped acquiring, it would still take many years to recover the intangibles. Why do I continue to hold? Inertia partly. I did sell a good chunk at 59.5p when the opportunity arose a couple of years ago and I think patience will see us back over that level - 'When?' I hear you ask.
mazarin: The timing of such news is always going to be difficult, however 9 mins before close (16.21hrs) on last day of the week certainly 'leaves a bad taste'. APH's BoD will need to consider more transparency on the timetable leading up to this announcement to retain credibility. Regulatory Approval for any of their products (or disapproval) is a matter of some significance to share price value. Particularly when not long ago APH was anticipating £250mln 'potential sales of Diclectin across UK/European market with a differentiated product addressing an unmet need.' For details, see:
arf dysg: I notice that the International Misery Fund said that we're screwed, blued and tattooed. Putting it in slightly more formal language, the predictions for growth in the USA and the UK have gone down a little. Perhaps that's why everyone's taking drugs as if there's no tomorrow, so the APH share price has gone up.
pollnagorm: Share price interests me not his finances , not to be rude about it .
pimpernel4: Fair enough and good luck to you ramridge. There seems to have been plenty of appetite at 44p this morning at just a 10% premium to the placement price. The compelling thing about APH is its relatively small free float of shares. As we saw earlier in the year it does not take much to get it motoring and the majority of the new shares must surely now sit in hands that are in it for the mid to long term. Let's see what the end of year share price is.
cisk: Michael, many thanks for the excellent précis. It really chimes with my earlier posts as to what's behind the share price rise - i.e. no specific reason but a combination of favourable factors. I've seen JD present - and had lengthy post-presentation conversations a handful of times and he's always refreshing, affable, to the point and cautiously optimistic. I suspect the share price got ahead of itself a little; and suspect we'll see a decline to late 40s / early 50s with no acquisition news. Regardless, it's a great company with solid prospects and one to tuck away. Thanks again.
michaelmcandrew: Attended this evening's Shares Magazine presentation by John Dawson. His input was about the company in general with no new financial information. His figures were taken from the 2014 annual results so I won't rehash them - they are all in the annual report. He was obviously constrained about revealing new information by the impending interim results in early September. [So, a strange time to do the presentation?] The Q&A were interesting [but not surprising for those of us who have heard JD speak in the past] :- * APH has facilities of £18m approved and available for purchases * any acquisitions will be established products with no marketing risk * before a product is bought in there is a very extensive due diligence process to try and ensure that there has been no cooking of the books by the vendor * there is no R&D spend because APH doesn't do R&D but they do spend extensively on promotion [within limits that do not damage profitability] * It is capitalism when a company is bought because it has a higher break-up value than it's cost. APH would rely on shareholders perception of future prospects to ward off any approach * JD knows of nothing driving the recent rise in the share price. Suggested that the company had treaded water and faced headwinds over the past 3 or 4 years resulting in nervousness amongst investors. He thought that there was now a perception that the headwinds had abated leading to the rise in share price. There had been a number of very large purchases recently.
mazarin: I find it odd to find ADVFN regularly 'mis-quote' APH share Price by as much as 3% at times. Today for example APH opened up 1.25p at 43p, but ADVFN show it as unchanged at 41.8p, both Google and APH's own webpage show it at 43p.
Alliance Pharma share price data is direct from the London Stock Exchange
add chat code
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180921 07:41:42